First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.
Kyriakos P. Papadopoulos(Texas Oncology), Glenn S. Kroog(Regeneron (United States)), Derrick Bramble(Regeneron (United States)), Amy‐Lee Bredlau(Regeneron (United States)), Tasha N. Sims(Regeneron (United States)), Afshin Dowlati(University Hospitals of Cleveland), Susanna V. Ulahannan(Oklahoma State University Oklahoma City), Melissa L. Johnson(Tennessee Oncology), Ana Gonzalez Ortiz(Regeneron (United States)), Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Haeseong Park(Brigham and Women's Hospital), Karen Kelly(Cancer Research Center), Maria Karasarides(Regeneron (United States)), Ding Wang(Henry Ford Hospital), Huanyu Chen(Regeneron (United States)), Filipa Lynce(Institut Claudius Regaud), Min Zhu(Regeneron (United States)), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics)
Cited by 38
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817